We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Model Identifies Sex-Specific Risks Associated with Brain Tumors

By LabMedica International staff writers
Posted on 10 Oct 2024

For years, cancer researchers have observed that men are more likely than women to develop glioblastoma, a deadly and aggressive form of brain cancer with a median survival of just 15 months after diagnosis. More...

Additionally, these tumors tend to be more aggressive in men. However, identifying specific characteristics that could help predict which tumors will grow faster has remained a challenge. Now, researchers are turning to artificial intelligence (AI) to uncover these risk factors and explore how they differ between men and women.

Scientists at the University of Wisconsin–Madison (Madison, WI, USA) are utilizing AI's computational capabilities to analyze large datasets of medical images, aiming to find patterns that could assist oncologists in making more informed decisions for their patients. Their goal is to address the entire range of challenges that cancer patients face, from diagnosis and prognosis to assessing treatment response. In this study, the researchers focused on digital images of pathology slides—thin sections of tumor samples—in an effort to detect patterns that might predict how fast a tumor could grow and, consequently, how long a patient might survive. Accurate prognosis is critical, as it influences treatment decisions and impacts patients’ quality of life after diagnosis.

To tackle this problem, the researchers developed an AI model capable of detecting subtle patterns in pathology slides that might be imperceptible to the human eye. They trained the model using data from over 250 glioblastoma studies, teaching it to recognize distinctive tumor features such as the abundance of certain cell types and the extent of the tumor’s invasion into nearby healthy tissue. Additionally, the model was trained to identify correlations between these features and patients' survival times, while also considering their sex. Through this approach, the team created an AI model that can identify risk factors for more aggressive tumors, with distinct patterns associated with each sex.

For women, higher-risk characteristics identified by the AI model included tumors that were infiltrating into healthy tissue. In men, the presence of pseudopalisading cells—cells that surround dying tissue—was linked to more aggressive tumors. The researchers' initial findings, published in Science Advances, revealed that the model also detected tumor traits associated with poorer prognoses for both sexes. The team is now extending their work to MRI data and has started using AI to analyze other cancers, such as pancreatic and breast cancers, with the goal of improving patient outcomes. This study could pave the way for more personalized treatment approaches for glioblastoma patients.

“There’s a ton of data collected in a cancer patient’s journey,” said radiology and biomedical engineering professor Pallavi Tiwari. “Right now, unfortunately, it’s usually studied in a siloed fashion, and this is where AI has huge potential. By uncovering these unique patterns, we hope to inspire new avenues for personalized treatment and encourage continued inquiry into the underlying biological differences seen in these tumors.”


New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Portable Electronic Pipette
Mini 96
Hemodynamic System Monitor
OptoMonitor
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.